Update on ropinirole in the treatment of Parkinson’s disease

References

• EdenRJCostallBDomeneyAMPreclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonistPharmacol Biochem Behav1991381471541673248
   PubMed Web of Science ®Google Scholar
• de MeyCEnterlingDMeinekeIYeuletSInteractions between domperidone and ropinirole, a novel dopamine D2-receptor agonistBr J Clin Pharmacol1991324834881683559
   PubMed Web of Science ®Google Scholar
• EdenRJWallduckMSPatelBOwenDAAutonomic and haemodynamic responses to SK&F 101468 (ropinirole), a DA2 agonist, in anaesthetised catsEur J Pharmacol19901753333401969802
   PubMed Web of Science ®Google Scholar
• ParkerSGRavalPYeuletSEdenRJTolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonistEur J Pharmacol199426517267883025
   PubMed Web of Science ®Google Scholar
• ActonGBroomCA dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonistBr J Clin Pharmacol1989284354412574051
   PubMed Web of Science ®Google Scholar
• IidaMMiyazakiITanakaKKabutoHIwata-IchikawaEOgawaNDopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonistBrain Res1999838515910446316
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJKorczynADDe DeynPPClarkeCELangAEA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med20003421484149110816186
   PubMed Web of Science ®Google Scholar
• WhoneALWattsRLStoesslAJSlower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET studyAnn Neurol2003549310112838524
   PubMed Web of Science ®Google Scholar
• KuzelMDRopinirole: a dopamine agonist for the treatment of Parkinson’s diseaseAm J Health Syst Pharm19995621722410030505
   PubMed Web of Science ®Google Scholar
• BoothmanBRSpokesEGPharmacokinetic data for ropiniroleLancet19903368141976175
   PubMed Web of Science ®Google Scholar
• SwagzdisJEWittendorfRWDeMarinisRMMicoBAPharmacokinetics of dopamine-2 agonists in rats and dogsJ Pharm Sci1986759259283795020
   PubMed Web of Science ®Google Scholar
• ThalamasCTaylorABrefel-CourbonCEagleSFitzpatrickKRascolOLack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson’s diseaseEur J Clin Pharmacol19995529930310424323
   PubMed Web of Science ®Google Scholar
• KayeCMNichollsBClinical pharmacokinetics of ropiniroleClin Pharmacokinet20003924325411069211
   PubMed Web of Science ®Google Scholar
• BrefelCThalamasCRayetSEffect of food on the pharmacokinetics of ropinirole in parkinsonian patientsBr J Clin Pharmacol1998454124159578193
   PubMed Web of Science ®Google Scholar
• RamjiJVKeoghJPBlakeTJDisposition of ropinirole in animals and manXenobiotica19992931132510219970
   PubMed Web of Science ®Google Scholar
• HubbleJKollerWCAtchisonPLinear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson’s diseaseJ Clin Pharmacol20004064164610868315
   PubMed Web of Science ®Google Scholar
• TompsonDJVearerDSteady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s diseaseClin Ther2007292654266618201581
   PubMed Web of Science ®Google Scholar
• AdlerCHSethiKDHauserRARopinirole for the treatment of early Parkinson’s disease. The Ropinirole Study GroupNeurology1997493933999270567
   PubMed Web of Science ®Google Scholar
• BrooksDJAbbottRJLeesAJA placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s diseaseClin Neuropharmacol1998211011079579296
   PubMed Web of Science ®Google Scholar
• KorczynADBrooksDJBruntERPoeweWHRascolOStocchiFRopinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study. 053 Study GroupMov Disord19981346519452325
   PubMed Web of Science ®Google Scholar
• HauserRARascolOKorczynADTen-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopaMov Disord2007222409241717894339
   PubMed Web of Science ®Google Scholar
• LiebermanAOlanowCWSethiKA multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study GroupNeurology199851105710629781529
   PubMed Web of Science ®Google Scholar
• ImJHHaJHChoISLeeMCRopinirole as an adjunct to levodopa in the treatment of Parkinson’s disease: a 16-week bromocriptine controlled studyJ Neurol2003250909612527999
   PubMed Web of Science ®Google Scholar
• PahwaRStacyMAFactorSARopinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson diseaseNeurology2007681108111517404192
   PubMed Web of Science ®Google Scholar
• FruchtSRogersJDGreenePEGordonMFFahnSFalling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropiniroleNeurology1999521908191010371546
   PubMed Web of Science ®Google Scholar
• WeintraubAKoesterJPotenzaMNDopaminergic therapy and impulse control disorders in Parkinson’s disease: Top line results of a cross sectional study of over 3,000 patientsMovement Disorder Society’s 12th International Congress of Parkinson’s disease and Movement DisordersChicago, Il2008
   Google Scholar
• SchapiraAHVStocchiFHunterBGiorgiLComparison of adjunctive ropinirole 24-hour prolonged release and immediate release in patietns with advanced Parkinson’s disease: A per-protocol analysis ofthe PREPARED studyMov Disord200823S196S197
   Web of Science ®Google Scholar
• StocchiFTompsonDJGiorgiLDosing of ropinirole 24-hour prolonged release in Parkinson’s disease: Clinical trial data and relevance to clinical practiceMov Disord200823S214
   Web of Science ®Google Scholar
• GoetzCGBlasucciLStebbinsGTSwitching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow?Neurology1999521227122910214748
   PubMed Web of Science ®Google Scholar
• EdinHMDeBenedettiDBHillCDAdherence among Parkinson’s disease patietns taking ropinirole immediate release at least thrice dailyMov Disord200823S344S345
   Web of Science ®Google Scholar